Monitor ASCO 2026 abstract presentations for detailed efficacy and safety data, particularly the STS-J01 Phase 2/3 results and the Phase 1 GCT trial design. Positive data could support label expansion into AYA and adult populations, but no near-term revenue catalyst is present in this filing.
Price Chart
Executive Summary
Fennec Pharmaceuticals announced that four independently led studies on PEDMARK (sodium thiosulfate injection) will be presented at the 2026 ASCO Annual Meeting. The research expands the evidence base for PEDMARK in adolescent, young adult, and adult patient populations, including a Phase 1 trial in metastatic germ cell tumors, positive Phase 2/3 results from Japan showing a significant reduction in hearing loss, and real-world data in head and neck cancers. This is a routine pipeline update with no financial data or regulatory catalysts disclosed.
Key Facts
- Four independent studies on PEDMARK will be presented at the 2026 ASCO Annual Meeting.
- The STS-J01 Phase 2/3 trial (27 patients) met its primary endpoint: hearing loss in 16-24% of PEDMARK patients vs. 56-63% historically with cisplatin alone.
- A randomized Phase 1 trial of PEDMARK in metastatic germ cell tumors opened to accrual at City of Hope in January 2026.
- Real-world data from 15 head and neck cancer patients showed PEDMARK could be safely given six hours after cisplatin with hearing preservation.
- No financial figures, revenue data, or guidance were provided in the filing.
Financial Impact
No financial figures disclosed; the filing is a clinical/regulatory update with no revenue or cost data.
Risk Factors
- Clinical data may not replicate in larger or more diverse patient populations.
- Label expansion into adult indications would require additional FDA submissions and approvals.
- Competing otoprotection agents or evolving clinical guidelines could limit market adoption.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-065696 |
| Document: fencf-20260521xex99d1.htm | 0001104659-26-065696 |
| Document: 0001104659-26-065696-index-headers.html | 0001104659-26-065696 |
| Document: 0001104659-26-065696-index.html | 0001104659-26-065696 |
| Document: 0001104659-26-065696.txt | 0001104659-26-065696 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | SC 13G/A | $10.27 | awaiting T+60 | — | $10.30 (+0.29%) |
Aug 31, 2026 8w ago | Insider Cluster | $12.03 | awaiting T+60 | — | $10.30 (−14.38%) |
Aug 31, 2026 8w ago | Insider Cluster | $12.03 | awaiting T+60 | — | $10.30 (−14.38%) |
Aug 11, 2026 11w ago | Press Release | $12.78 | awaiting T+60 | — | $10.30 (−19.41%) |
Jun 15, 2026 19w ago | Press Release | $9.19 $11.65 | ▲ +26.77% | ▲ +25.77% | $10.30 (+12.08%) |
May 22, 2026 22w ago | 8-K | $9.89 $11.87 | ▲ +20.02% | ▲ +17.30% | $10.30 (+4.15%) |
May 18, 2026 23w ago | 8-K | $9.76 $12.06 | ▲ +23.57% | ▲ +17.28% | $10.30 (+5.53%) |
May 14, 2026 23w ago | Press Release | $9.24 $10.94 | ▲ +18.40% | ▲ +14.81% | $10.30 (+11.47%) |
May 7, 2026 24w ago | Press Release | $6.90 $9.59 | ▲ +38.99% | ▲ +35.15% | $10.30 (+49.28%) |
Apr 28, 2026 25w ago | 8-K | $6.26 $9.99 | ▲ +59.58% | ▲ +55.47% | $10.30 (+64.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers